



Example of Treatment Algorithm for Atopic Dermatitis: AD Yardstick



*Poorly or inadequately controlled signs and symptoms of AD.
**Before stepping up therapy, the patient should be assessed for nonadherence, potential comorbidities, and other factors that might negatively affect response to therapy. ¹Indicated for patients at least 2 years old with mild to moderate AD. ³Indicated for patients at least 18 years old with moderate to severe AD. It is the authors' expert opinion that dupilumab has a safety and efficacy profile that is better than that of immunosuppressive agents or phototherapy; cost and coverage are extremely important considerations.⁴Not approved. ⁵Approved to treat AD but not recommended for long-term maintenance.
Boguniewicz M, et al. *Ann Allergy Asthma Immunol.* 2018;120:10-22.